PURPOSE: Past reports indicate that alpha hemolytic streptococcal (AHS) organisms are a common cause of infection among acute myeloid leukemia (AML) patients. This study was intended to ascertain the ...

While inhalation of naphthalene due to exposure to mothballs, in and of itself, may be a cause of severe hemolysis, glucose-6-phosphate dehydrogenase (G-6-PD) deficiency is more commonly ...

Hemolysis is a significant complication of extracorporeal membrane oxygenation (ECMO), with a reported incidence of 12.2%. The aims of this study were (1) to investigate hemolysis caused by saline ...

Breakthrough hemolysis may be attributed to suboptimal C5 inhibition; its cause may be pharmacokinetic (due to low levels of eculizumab 27) or pharmacodynamic, as when infection or inflammation ...

Hemolysis is the destruction of red blood cells (RBCs). Typically, RBCs can live for up to 120 days before the body naturally destroys them. However, certain conditions and medications may cause ...

To manage patients’ hemolysis, 68% (n = 13) underwent a dose increase of pegcetacoplan from twice weekly to 1080 mg every 3 days. This approach reportedly benefited 6 patients’ hemolytic outcomes.

Identify data and insights on the impact of hemolysis in whole blood potassium testing; Outline the specific patient care impact of hemolysis in emergency and neonatal care; Discuss the experience of ...

In this presentation, we will review common pre-analytical causes of hemolysis and how hemolysis impacts different clinical chemistry analytes. The presentation will conclude by discussing Special ...

Hemolysis is not the only factor that should be considered when thinking about limiting PFA deliveries, she responded. “Because it’s fast and probably safe doesn’t mean that we should do extensive ...

To the Editor: The letter to the Editor by Berzuini et al. (Sept. 2 issue)1 shows in a single example that in patients with paroxysmal nocturnal hemoglobinuria (PNH) who are receiving eculizumab, ...

WILMINGTON, Del. — Positive results from the 24-week and long-term extension (LTE) period of the pivotal ALPHA Phase III trial showed danicopan as add-on to standard of care C5 inhibitor therapy ...